Clinical Trial Update: A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome [Phase 4]

View source ↗

Summary

Phase IV study of BMS-232632 in HIV-infected patients with metabolic syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Metabolic Syndrome

Drugs mentioned

• BMS-232632

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 4 | Status: TERMINATED